NCT03310021View on ClinicalTrials.gov

A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

August 13, 2019

Study Completion Date

August 13, 2019

Conditions
Bleeding
Interventions
BIOLOGICAL

Andexanet alfa

fXa inhibitor antidote

DRUG

Apixaban

factor Xa inhibitor

DRUG

Rivaroxaban

factor Xa inhibitor

DRUG

Edoxaban

factor Xa inhibitor

DRUG

Placebo

Placebo

Trial Locations (1)

90630

WCCT Global, Cypress

Sponsors
All Listed Sponsors
lead

Portola Pharmaceuticals

INDUSTRY

NCT03310021 - A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects | Biotech Hunter | Biotech Hunter